Upload resources

Upload your works to SEDICI to increase its visibility and improve its impact


Show simple item record

dc.date.accessioned 2020-08-13T17:44:03Z
dc.date.available 2020-08-13T17:44:03Z
dc.date.issued 2016-03
dc.identifier.uri http://sedici.unlp.edu.ar/handle/10915/102264
dc.description.abstract Levofloxacin (LV) is a hydrophilic broad-spectrum antibiotic commonly used in pulmonary treatment against recurrent infections of Pseudomonas aeruginosa, and particularly in cystic fibrosis (CF) disease. In order to study feasible carriers for LV, solid lipid nanoparticles (SLN) of myristyl myristate were prepared by the ultrasonication method in the presence of Pluronic®F68 under different experimental conditions and characterized by dynamic light scattering, optical, transmission and scanning electron microscopy for size and morphology. Alternatively, nanostructured lipid carriers (NLCs) were developed to improve LV encapsulation and storage. SLN showed 20.1 ± 1.4% LV encapsulation efficiency, while the NLCs encapsulated 55.9 ± 1.6% LV. NLC formulation exhibited a more controlled release profile than SLN formulation, but both showed a biphasic drug release pattern with burst release at the first 5 h and prolonged release afterwards, demonstrated by in vitro tests. The hydrodynamic average diameter and zeta potential of NLC were 182.6 ± 3.2 nm and -10.2 ± 0.2 mV, respectively, and were stable for at least 3 months. Additionally, DNase type I was incorporated into the formulations as a "smart" component, since the enzyme could help to decrease the viscoelasticity found in the lungs of CF patients and improves the antibiotic diffusion. FTIR, XRD, DSC, TGA and nitrogen adsorption isotherms of the nanoparticles indicate the presence of the loads in a noncrystalline state. The developed formulation showed an active antimicrobial activity against P. aeruginosa and even against other opportunistic pathogens such as Staphylococcus aureus. The presence of LV-loaded NLCs reduced the formation of a bacterial biofilm, which highlighted the significance of the nanodevice as a new alternative for CF treatment. en
dc.format.extent 168-176 es
dc.language en es
dc.subject Cystic fibrosis es
dc.subject DNase es
dc.subject Levofloxacin es
dc.subject Nanostructured lipid carriers es
dc.subject Pulmonary delivery es
dc.subject Solid lipid nanoparticles es
dc.title Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery: design and characterization en
dc.type Articulo es
sedici.identifier.uri https://ri.conicet.gov.ar/11336/40036 es
sedici.identifier.other https://doi.org/10.1016/j.colsurfb.2016.03.040 es
sedici.identifier.other hdl:11336/40036 es
sedici.identifier.issn 0927-7765 es
sedici.creator.person Islan, Germán Abel es
sedici.creator.person Cortez Tornello, Pablo Roberto es
sedici.creator.person Abraham, Gustavo Abel es
sedici.creator.person Duran, Nelson es
sedici.creator.person Castro, Guillermo Raúl es
sedici.subject.materias Química es
sedici.description.fulltext true es
mods.originInfo.place Centro de Investigación y Desarrollo en Fermentaciones Industriales es
sedici.subtype Preprint es
sedici.rights.license Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
sedici.rights.uri http://creativecommons.org/licenses/by-nc-sa/4.0/
sedici.description.peerReview peer-review es
sedici.relation.journalTitle Colloids and Surfaces B: Biointerfaces es
sedici.relation.journalVolumeAndIssue vol. 143 es

Download Files

This item appears in the following Collection(s)

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) Except where otherwise noted, this item's license is described as Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)